Compare
Minerva Neurosciences, Inc. vs iBio, Inc. vs Citius Oncology, Inc. vs Arbutus Biopharma Corp
| Latest fiscal year | Minerva Neurosciences, Inc. NERVRevenue covers only part of its income (partial revenue) | iBio, Inc. IBIO | Citius Oncology, Inc. CTOR | Arbutus Biopharma Corp ABUS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-09-30 | 2025-12-31 |
| Revenue | n/a | $100.0K | n/a | $14.08M |
| Revenue growth (YoY) | n/a | -75.0% | n/a | +128.2% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/a | -271.0% |
| Net margin | n/a | n/m | n/a | -237.9% |
| Net income | -$293.42M | -$33.04M | -$24.76M | -$33.50M |
| EPS (Diluted) | -$34.67 | -$0.32 | -$0.34 | -$0.17 |
| Operating cash flow | -$13.51M | -$23.22M | -$5.49M | -$39.64M |
| Free cash flow | n/a | -$23.80M | n/a | -$39.64M |
| Cash & equivalents | $82.30M | $56.40M | n/a | $18.01M |
| Total assets | $97.97M | $99.11M | $100.94M | $94.62M |
| Total liabilities | $233.76M | $13.40M | $56.08M | $18.04M |
| Shareholders' equity | -$140.75M | $85.71M | $44.87M | $76.58M |
| Return on year-end equity | n/a | -38.6% | -55.2% | -43.7% |
| Shares outstanding | 43.27M | 55.70M | 83.51M | 192.53M |
Revenue, most recent five fiscal years
| Fiscal year | Minerva Neurosciences, Inc. | iBio, Inc. | Citius Oncology, Inc. | Arbutus Biopharma Corp |
|---|---|---|---|---|
| Latest | n/a | $100.0K Ended 2026-06-30 | n/a | $14.08M Ended 2025-12-31 |
| 1 year earlier | n/a | $400.0K Ended 2025-06-30 | n/a | $6.17M Ended 2024-12-31 |
| 2 years earlier | n/a | $225.0K Ended 2024-06-30 | n/a | $18.14M Ended 2023-12-31 |
| 3 years earlier | n/a | $0 Ended 2023-06-30 | n/a | $39.02M Ended 2022-12-31 |
| 4 years earlier | n/a | $1.88M Ended 2022-06-30 | n/a | $10.99M Ended 2021-12-31 |